Save Product
Product Details
Synonyms
CD8A, CD8, Leu2, MAL, p32
Source
Biotinylated Human CD8 alpha, His,Avitag (CDA-H82E3) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 (Accession # P01732-1).
Predicted N-terminus: Ser 22
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 21.2 kDa. The protein migrates as 25-32 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
The protein is designed as a dimer.
Conjugate
Biotinylated
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
0.7-1.0 as determined by the SABA assay / HABA assay / binding ELISA.
Endotoxin
Less than 0.1 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human CD8 alpha, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Biotinylated Human CD8 alpha, His,Avitag (Cat. No. CDA-H82E3) is more than 90% and the molecular weight of this protein is around 45-65 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Biotinylated Human CD8 alpha, His,Avitag (Cat. No. CDA-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate. can bind Anti-CD8 alpha Antibody, Mouse IgG2a (clone: OKT8) with a linear range of 0.2-2 ng/mL (QC tested).
Protocol
Immobilized Anti-CD8 alpha Antibody, Mouse IgG2a (clone: OKT8) at 1 μg/mL (100 μL/well) can bind Biotinylated Human CD8 alpha, His,Avitag (Cat. No. CDA-H82E3) with a linear range of 1-39 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Cluster of differentiation 8
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
18 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
